Chairman of HymonBio Listed on “Good People of Taicang”

News

Chairman of HymonBio Listed on “Good People of Taicang”

On the afternoon of April 28th, the first “Good People of Taicang” press conference and on-site exchange activities between moral models and good people around them (at Loudong Street) were held in the Citizen Park. Zha Yan, member of the Standing Committee of the Municipal Party Committee, director of the Propaganda Department and director of the United Front Work Department, attended the event.

During the event, the first issue of “Good People of Taicang” list for 2023 was officially released. Included in the list is Dr. Tammy Tan, chairman of HymonBio.

WeChat Image_20230504160642

WeChat Image_20230504160647

At the event, Minister Cha presented the “Good People of Taicang” and “Family Heirloom” trophies.

WeChat Image_20230504160650

Tammy Tan, born in 1978, is a member of the Communist Party of China and of the Medical Laboratory Expert Committee of the National Health Industry Enterprise Management Association. She currently resides in Taicang and is the chairman of HymonBio Co., Ltd. For over a decade, she has been engaged in research based on gene expression regulation and cancer pathogenesis, as well as the development of diagnostic reagents in the field of emerging infectious diseases. In 2015, she returned to China to start her own business. She has mastered the relevant core technologies in the development and application of gene precision diagnosis, nucleic acid screening system, original trace nucleic acid enrichment technology, nanomolecular lock nucleic acid amplification technology and nucleic acid multiplex detection technology and other precision diagnostic detection technologies, cracked the international technical difficulties of mutation and disease-specific early tumor nucleic acid markers for microdetection and simultaneous detection of multi-gene projects, and can achieve early screening and identification of complex multi-site gene markers such as malignant tumors and multiple infections of major infectious diseases. HymonBio has applied for 36 patents, obtained 16 authorized patents, 11 products have obtained China medical device certificate, 9 products have obtained EU CE certificate, and 1 product has obtained FDA EUA certificate.


Post time: May-04-2023